Keyword: Genentech

The upfront sets the Roche subsidiary up to incorporate the candidates into its immuno-oncology combination strategy.

GSK chairman bows out; Editas CEO signs off; Roche dispatches exec to take over Genentech; and Vertex fires COO for code of conduct violation.

Though Erasca raised $40 million to bankroll its work to “not just treat, but actually cure cancer," it's keeping mum on the specifics.

Inflazome has brought on Thomas Jung, M.D., Ph.D., to be its new chief medical officer and lead clinical development of its NLRP3 inhibitors.

Roche launched an in vitro diagnostic to detect tropomyosin receptor kinase proteins in cancer, with potential use in a range of solid tumor types.

Genentech acquired Jecure Therapeutics and its stable of NLRP3 inhibitors for an undisclosed amount.

Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.

The deal gives the Roche subsidiary at least a partial stake in the preclinical MAGE-A4-targeting drug IMC-C103C.

Nektar Therapeutics poached Genentech immunotherapy leader Wei Lin to head up its oncology program and serve as VP of clinical development.

Intellia clinical head to be Casebia’s first CMO; Ferring CSO to take over for retiring board president; and Harpoon names new CFO and CSO.